AVANT Immunotherapeutics Inc. (Nasdaq: AVAN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AVANT Immunotherapeutics Inc. (Nasdaq: AVAN)

AVAN 10.04

0.0%

Jun 12 9:41 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: SLOJET who wrote (280)	1/30/2000 3:38:00 PM
From: John McCarthy	Read Replies (1) of 513

Investors Business Daily - Friday - 1/28/2000 Note:I have posted the following on Yahoo this morning Date:Janueary 28, 2000 Section:B Page:B1 .... Title:Biotech Boom ... A Promising Pipeline Of New Remedies Is a Bullish Trend For The Sector fast-forward to page b2, Column 6 Avant Immunotherapeutics. ========================================= This tiny $302 million (market cap) company also has two potential blockbusters in its pipeline. TP-10 and CETi-1, or CETP, Naqvi said. TP-10 is a "complement- inhibitor" drug that targets inflammatory tissue damage. It basically defends the body from autooimmune reactions in which "the body attacks itself," Naqvi said. Avant, based i Needham, Mass. says TP-10 could be used to treat rheumatoid arthritis, multiple sclerosis and organ transplant patients. CETi is a cholesterol-lowering vaccine targeting people with heart disease. Naqvi says CETi-1 has a chance of being bigger than Lipitor, one of the worlds top-selling drugs. The reason:CETi-1 requires only two injections a year, whereas Lipitor is an oral drug that must be taken daily. Thats it. regards, John McCarthy

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next